Summary

Eligibility
for females ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
study ends around
Principal Investigator
by Jocelyn Chapman (ucsf)
Headshot of Jocelyn Chapman
Jocelyn Chapman

Description

Summary

The goal of this clinical trial is to determine if NTB-928 can be given safely to adult females with ovarian cancer that has come back (relapsed) or stopped responding to treatment (refractory), how NTB-928 moves through the body, and how the immune system reacts to it. The study will also look for early signs of anti-cancer activity of NTB-928. The main questions the study aims to answer are:

  • What side effects do participants experience when receiving NTB-928, including side effects that limit how much of it can be safely given?
  • How is NTB-928 processed by the body at different dose levels?
  • Does the immune system react to NTB-928 during treatment?
  • What dose of NTB-928 can be given safely that shows early signs of activity against ovarian cancer?

Official Title

A Phase 1 Multicenter, Open-Label, Dose-Escalation and Expansion Study of NTB-928, a FRα-Targeting Bispecific T Cell Engager, in Subjects With Relapsed/Refractory Ovarian Carcinoma

Keywords

Relapsed/Refractory Ovarian Carcinoma, Ovarian Cancer, Ovarian Carcinoma, High Grade Serous Ovarian Carcinoma, Endometrioid Ovarian Carcinoma, Low Grade Serous Ovarian Carcinoma, Ovarian Carcinosarcoma, Clear Cell Carcinoma of the Ovary, Ovarian Neoplasms, NTB-928

Eligibility

You can join if…

Open to females ages 18 years and up

  • Aged 18 years or older
  • Have a confirmed diagnosis of ovarian cancer, including high-grade serous, high-grade endometrioid, low-grade serous, or clear cell ovarian cancer, or carcinosarcoma of the ovary. Patients with mucinous carcinoma are not eligible.
  • Have relapsed or refractory ovarian cancer and have already received standard treatments known to provide benefit; participants are eligible if they have platinum-refractory, platinum-resistant, or platinum-sensitive ovarian cancer (with clearly documented ineligibility for further platinum chemotherapy).
  • Are able to understand the study requirements and are willing to provide written informed consent
  • Are willing to use effective birth control during the study and for a period after the last dose of study treatment, if of childbearing potential

You CAN'T join if...

  • Have another active cancer that could interfere with assessment of this study treatment
  • Have received another investigational drug or certain cancer treatments within a recent period before starting this study
  • Are pregnant or breastfeeding

Locations

  • University of California San Francisco Health - Hereditary Cancer Clinic - Mission Bay accepting new patients
    San Francisco California 94158 United States
  • University of Colorado Anschutz Cancer Center - Anschutz Cancer Pavilion accepting new patients
    Aurora Colorado 80045 United States

Lead Scientist at University of California Health

  • Jocelyn Chapman (ucsf)
    Next-generation sequencing technologies developed in the last ten years have dramatically widened our view into the many kinds of events that are driving tumor biology. Gene fusions, copy number alterations, mutations, epigenetic changes and transcript level alterations can all be ascertained via the knife of DNA and RNA sequencing.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
TeneoSeven, Inc.
ID
NCT07690189
Phase
Phase 1 Ovarian Cancer Research Study
Study Type
Interventional
Participants
Expecting 90 study participants
Last Updated